Manisha Tiwari
Assistant Professor
Bio-Organic Chemistry
Dr B R Ambedkar Center for Biomedical Research
India
Biography
-
Research Interest
Dr Manisha Tiwari works focuses on the treatment of CNS and lifestyle disorders. The CNS disorders that we are working on include Alzheimer’s disease and epilepsy. Lifestyle disorders that we are researching include hyperlipidemia and cancer. Our laboratory works on the synthesis of small organic molecules for the treatment of these disorders. In the last 10 years we have synthesis several therapeutic agents for the treatment of Alzheimer’s Disease. One of the essential pharmacophores in our studies is aryl piperazine. We have prepared aryl piperazine derivatives, some of which have shown excellent activity against acetylcholinesterase and Abeta aggregation. In silico analysis of these derivatives including molecular docking studies and Molecular dynamics simulation studies have been carried out with A beta, which show strong interaction of these derivatives with the Abeta protein aggregates. We have also prepared heterocyclic compounds for the treatment of cancer which have shown admirable activity in vivo
Publications
-
3. Novel Insights into Multitargeted Potential of N'-(4-benzylpiperidin-1-yl)alkylamine derivatives in the Management of Alzheimer's Disease Associated Pathogenesis Poonam Meena, Apra Manral, Manisha Tiwari* RSC Advances, 2016, 6, 104847 – 104867 Impact Factor 3.84
-
2. Design, Synthesis, In Silico and Biological Evaluation of Novel 2-(4-(4-substituted piperazin-1-yl)benzylidene carboxamidesShikha Kumari, Chandra Bhushan Mishra, Danish Idrees, Amresh Prakash • Rajesh Yadav • Md. Imtaiyaz Hassan • Manisha Tiwari* Molecular Diversity 2016 (Accepted) IF 1.9
-
1. Novel Triazole-Piperazine Hybrid Molecules Induce Apoptosis via Activation of the Mitochondrial Pathway and Exhibit Anti-tumor Efficacy in Osteosarcoma Xenograft Nude Mice Model Chandra Bhushan Mishra Raj Kumar Mongre,; Shikha Kumari; Dong Kee Jeong ; Manisha Tiwari*: ACS Chemical Biology (accepted ) 2017 IF 5.09
